Sionna Therapeutics (SION) Cash from Financing Activities (2024 - 2026)

Sionna Therapeutics has disclosed Cash from Financing Activities across 3 years of filings, most recently posting $1.9 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $1.9 million, down 99.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 97.39% YoY), and the FY2025 annual result was $205.7 million, up 14.94% from the prior year.
• Cash from Financing Activities came in at $1.9 million for Q1 2026 at Sionna Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $202.4 million in Q1 2025 to a low of -$1.4 million in Q4 2024.
• The 3-year median for Cash from Financing Activities is $1.7 million (2025), against an average of $43.0 million.
• Peak annual rise in Cash from Financing Activities reached 298.19% in 2025, while the deepest fall reached 921.05% in 2025.
• Sionna Therapeutics' Cash from Financing Activities stood at -$1.4 million in 2024, then surged by 217.83% to $1.7 million in 2025, then advanced by 14.1% to $1.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.9 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.